The present standard of care for acute ischemic stroke is restricted to reperfusion interventions including endovascular thrombectomy and intravenous thrombolysis, primarily with tissue plasminogen activator (tPA), which mitigate stroke-related disability and mortality in a significant proportion of selected patients (4, 5). The gene discussed is PLAT; the disease is Stroke.